Navigation Links
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood

f the hydrochlorothiazide component, AVALIDE is

contraindicated in patients with anuria or hypersensitivity to

sulfonamide-derived drugs

-- In patients with volume or sodium depletion (eg, patients vigorously

treated with diuretics or on dialysis), such depletion should be

corrected prior to administration of AVAPRO(R) (irbesartan) or

AVALIDE(R) (irbesartan-hydrochlorothiazide), or a lower initial dose of

AVAPRO (75 mg) should be used, to avoid possible symptomatic


-- Hypersensitivity reactions to hydrochlorothiazide may occur in patients

with or without a history of allergy or bronchial asthma, but are more

likely in patients with such a history

-- Thiazide diuretics have been reported to cause exacerbation or

activation of systemic lupus erythematosus

-- Lithium generally should not be given with thiazides

-- Thiazides should be used with caution in patients with severe renal

disease and in patients with impaired hepatic function or progressive

liver disease, since minor alterations of fluid and electrolyte balance

may precipitate hepatic coma

-- In placebo-controlled hypertension studies, there were no significant

differences in adverse events (AEs) between AVAPRO and

placebo. Adverse events that occurred in at least 1% of patients

treated with AVAPRO and at a higher incidence vs placebo included

diarrhea (3% vs 2%), dyspepsia/heartburn (2% vs 1%) and fatigue (4% vs


-- Additionally, in a study of hypertensive type 2 diabetic patients with

renal disease (proteinuria greater than or equal to 900 mg/day), the

reported AEs for AVAPRO were similar to those seen in hypertension

studies, with the exception of an increased incidence of orthostatic

symptoms; AVAPRO compared to placebo (both groups received adjunc

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
(Date:10/9/2015)... ,JCA-Mauvernay Award 2015, se ha otorgado a los doctores ... Takita    --> El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... los doctores Yutaka Kondo y ... con sede enSuiza, presentará el ,JCA-Mauvernay Award, el 10 de octubre a los ...
(Date:10/8/2015)... Calif. , Oct. 8, 2015  "They really ... of her Kaiser Permanente care team, after a ... a treatment plan for cancer. The 79-year-old Kaiser Permanente ... , went in for what she thought was ... her physician and care team, however, she was diagnosed ...
(Date:10/8/2015)... DUBLIN , Oct. 8, 2015  Allergan plc ... today announced that it will hold its R&D Day ... ET (8:00 a.m. – to 1:00 p.m. PT). The ... and webcast beginning at 9:00 a.m. ET (6:00 a.m. ... --> Logo - ...
Breaking Medicine Technology:
... RX-3341 Results -, NEW HAVEN, Conn., July ... a development-stage company focused on the,discovery and development ... today announced the initiation of a Phase,2 clinical ... RX-3341 in,the treatment of complicated skin and skin ...
... Alfacell Corporation,(Nasdaq: ACEL ) today announced ... with Megapharm Ltd., a leading pharmaceutical company ... in Israel. ONCONASE,the company,s lead drug candidate, ... trial for unresectable malignant,mesothelioma (UMM)., Under ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Isabel Healthcare will participate in the Cerner Health ... the release of the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel ... that assist healthcare providers and consumers to potentially reduce the chance of error. The ...
(Date:10/9/2015)... ... October 09, 2015 , ... Each year, over 600 ... pre-eminent organization in global health: the World Health Organization (WHO). At its core, ... internships are a mechanism for WHO to help build public health capacity in ...
(Date:10/9/2015)... ... 09, 2015 , ... Smoke alarms can save lives. In fact, according to ... dying in reported home fires in half. As part of Fire Prevention Week, ... installed and maintained. , Half of home fire deaths result from fires reported between ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS ... in Madrid, Spain. Representing both the USA and Sweden in the Speed and Power ... Am Front Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the fastest growing ... life to save money on the high cost of their prescription medications through ... individuals and families can receive their medications delivered direct from over 180 U.S.-based ...
Breaking Medicine News(10 mins):
... --, -- Revenues of $73.8 million, ... -- Net income of $12.8 million or $0.27 per ... (OTC Bulletin Board: LTUS, "Lotus" or the,"Company") today reported its ... up 30% from 2007 total net revenues; gross profit,increasing to ...
... San Francisco, Calif. - April 22, 2009 ... of "transplant tourism" (traveling abroad to purchase donor ... implementation of internationally accepted ethical standards for procurement ... in Clinical Transplantation finds that both ...
... can increase cancer risk, , , WEDNESDAY, April 22 (HealthDay ... new study finds. , That,s good news because it,s ... higher risk of breast cancer. A number of studies ... compounds) might increase breast density. However, there have been ...
... and Support, Offline Event Scheduled for June 6, 2009 ... A new social media site and comprehensive online ... to those faced with infertility or trying to conceive. ... of California octuplets and exciting medical breakthroughs such as ...
... coaches can prevent injuries in young baseball playersROSEMONT, Ill., April ... and also a great way for kids to get some ... the American Academy of Orthopaedic Surgeons ... keep ballplayers injury-free. , , ...
... Ethicon Endo-Surgery today announced ... granted approval of the company,s Investigational Device Exemption (IDE) ... for use in natural orifice translumenal endoscopic surgery (NOTES). ... IDE to investigate devices specifically designed for natural orifice ...
Cached Medicine News:
... Bard Brachytherapy loaders allow for ... and SourceLink™ Connectors to your customized ... advantage of Bard loaders is the ... "real-time" loading flexibility of the patented ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
... The BrachySource iodine-125 implant is a ... and remarkable visibility that makes BrachySource I-125 ... patients. You can be confident that every ... our seed management services which is required ...
... iodine-125 implant is a combination of innovative ... that makes BrachySource I-125 implant an ideal ... be confident that every BrachySource I-125 implant ... services which is required by clinicians who ...
Medicine Products: